FUTURE PATENT WARS

!"#$#%&'(#)*+',-)./"#'

!"#$"%&'()*'(+,-'

Beyond the Smartphone Battles and Bloodbath

#LESDolcera

Panelists

2

IP Analytics Internet Services & Products

Maximising IP Value

Computer Technology

Diverse Electronics

#LESDolcera

Dolcera Analytics

•  ./0'1233245#6'735807'/"90':00#'809032;08':&'<23=0%">7'?@'"#8'A"%B0C'"#"3&D=7'C0"A7'$75#6'2$%';%2;%50C"%&'"#"3&D=7';3"E2%A'

•  F0'4533'7$AA"%5G0'"'104'B0&'H$"#DC"D90';"%"A0C0%7'40'700'=2%%03"D#6'4033'4533'7;5B07'5#';"C0#C'3"47$5C7'

#LESDolcera

What is a Patent War?

0-"*12'3/41*5-1'I'@"C0#C'4"%7'"%0'0J2%C7':&'A"K2%'C0=/#2326&';3"&0%7'$75#6';"C0#C7'C2'5#=%0"70'2%'70=$%0'A"%B0C'7/"%0''6/#)'3/41*5-1'I'@"C0#C'4"%7'"%0'"'=2A;30L'C0=/#2M306"3':"N306%2$#8'4/0%0'A"K2%'632:"3'12%=07'=2A:"C'12%'7$;%0A"=&'"7'C/0'42%38'4"C=/07'

!"#$%&'()%*#+',%-&.$%$/0+1',%*#2'%2%32*$'*%42.%+5%*#$%630&-+',%5$25&'%&7%8&65$%&7%92.:5;%

Smartphone Patent Suits

Source – PCMag, January 2012 #LESDolcera

Lawsuit Prediction Modeling

•  Historical data on the Litigations was extracted and normalized.

•  Secondary research was conducted to obtain relevant data for the factors

Data Collection & Cleaning

•  Various factors were considered for possible correlation

Regression Analysis •  Based on the correlations,

a model was proposed & tested

•  The Model is 82% significant in explaining the variability of the factors

Drawing Inferences

Methodology:

#LESDolcera

O57C2%5="3'@"C0#C'P"47$5C'<"C"'

+' (+' Q+' R+' )+' ,++' ,(+'

?#C0%#0C'S1'./5#67'

F0"%":307'

@233$C"#C7'"#8'0J0=C7'2#'7B5#'"#8'/"5%'

T"#20A$3752#7'5#'12287'

U5=%2V$585=7'W'A5=%2;%2=0775#6'

.%"#780%A"3'8%$6'803590%&'

X#0%6&'Y"708'Z$%65="3'Z0"35#6'2%'<5770=D2#'

Z$%65="3'ZC";35#6'

ZA"%C;/2#07'

+' ,+' (+' [+' Q+' -+' R+' \+'

7&-89#139'

?#C0%#0C'S1'./5#67'

F0"%":307'@233$C"#C7'"#8'0J0=C7'2#'7B5#'

"#8'/"5%'

T"#20A$3752#7'5#'12287'

U5=%2V$585=7'W'A5=%2;%2=0775#6'

.%"#780%A"3'8%$6'803590%&'

X#0%6&'Y"708'Z$%65="3'Z0"35#6'2%'<5770=D2#'

Z$%65="3'ZC";35#6' ZA"%C;/2#07'

T$A:0%'21';"C0#C7' ,()(,' ,R+\' ,\\' Q+[' ,]R\' [,,[' )++[' ,)++' R++++'

T$A:0%''21'3"47$5C7'' ](' [Q' ]' R' ,' (R' ,R' ,(' ,,,'

:#;98*%9'<9'!#%/1%9'='>*)*12',#%/9?'@AAA'B'@ACD'

Source – Dolcera, January 2014 #LESDolcera

Model Implementation

No of patents

R&D Spend(in millions USD)

Hype Cycle

NPE

Operating Company

Significant Factors

No of patents

Revenue (in millions USD)

R&D Spend (in millions USD)

Hype Cycle

Non Practicing Entities

Operating Company

Individual inventors

Research Centers & Universities

Considered Influencing Factors

Regression Analysis

#LESDolcera

Predictive Model

The no. of lawsuits in area was found dependent on the factors as below:

No of lawsuits = -  1.027 + 0.0072 * No of patents

+ 0.0011 * R&D Spend (in Millions) - 0.0103 * Hype Cycle - 0.0009 * NPE + 0.0055 * Operating Company

Interactive Dashboard : Sensitivity Analysis

Source – Dolcera, January 2014 #LESDolcera

Real-world Examples

Hi Tech •  Internet of

Things •  Wearable

Devices

CPG •  Pollutants and

Effects on skin and hair

Pharma •  Microfluidics &

Micro processing

•  Transdermal Drug delivery

Medical Devices •  Energy Based

Surgical Sealing or Dissection

•  Surgical Stapling

Food & Beverages •  Nanoemulsions

in foods

#LESDolcera

O57C2%5="3'@"C0#C'P"47$5C'<"C"'

+' (+' Q+' R+' )+' ,++' ,(+'

?#C0%#0C'S1'./5#67'

F0"%":307'

@233$C"#C7'"#8'0J0=C7'2#'7B5#'"#8'/"5%'

T"#20A$3752#7'5#'12287'

U5=%2V$585=7'W'A5=%2;%2=0775#6'

.%"#780%A"3'8%$6'803590%&'

X#0%6&'Y"708'Z$%65="3'Z0"35#6'2%'<5770=D2#'

Z$%65="3'ZC";35#6'

ZA"%C;/2#07'

+' ,+' (+' [+' Q+' -+' R+' \+'

7&-89#139'

?#C0%#0C'S1'./5#67'

F0"%":307'@233$C"#C7'"#8'0J0=C7'2#'7B5#'

"#8'/"5%'

T"#20A$3752#7'5#'12287'

U5=%2V$585=7'W'A5=%2;%2=0775#6'

.%"#780%A"3'8%$6'803590%&'

X#0%6&'Y"708'Z$%65="3'Z0"35#6'2%'<5770=D2#'

Z$%65="3'ZC";35#6' ZA"%C;/2#07'

T$A:0%'21';"C0#C7' ,()(,' ,R+\' ,\\' Q+[' ,]R\' [,,[' )++[' ,)++' R++++'

T$A:0%''21'3"47$5C7'' ](' [Q' ]' R' ,' (R' ,R' ,(' ,,,'

:#;98*%9'<9'!#%/1%9'='>*)*12',#%/9?'@AAA'B'@ACD'

Direct Correlation between patent count & litigation Source – Dolcera, January 2014

#LESDolcera

Litigations over the years

M-'

+'

-'

,+'

,-'

(+'

(-'

@AAD' @AAE' @AAF' @AAG' @AAH' @AAI' @ACA' @ACC' @AC@' @ACJ' @ACD'

KL*9'7*%)/'

KL*9'7*%)/'

M8$N/"'-O':#;98*%9'

?#C0%#0C'S1'./5#67'

F0"%":30'

U5=%2V$585=7'W'U5=%2;%2=0775#6'

.%"#780%A"3'<%$6'803590%&'

X#0%6&'Y"708'Z$%65="3'Z0"35#6'2%'<5770=D2#'

U085="3'ZC";35#6'

T"#2M0A$3752#7'5#'12287'

Patent lawsuits in Wearables/IOT started before the Hype

Source – Dolcera, January 2014 #LESDolcera

Smartphone Patent Suits

Source – PCMag, January 2012 #LESDolcera

Pollutants and Effects On Skin & Hair

Source – Dolcera, January 2014

Low patent count, Medium R&D spend, Low Hype, Low NPEs

#LESDolcera

Nano-emulsions In Foods

Source – Dolcera, January 2014

Low patent count, Medium R&D spend, Low Hype, No NPEs

#LESDolcera

Surgical Stapling

Source – Dolcera, January 2014

Medium Patent Count, High R&D spend, Low Hype, Low NPEs

#LESDolcera

Energy Based Surgical Sealing or Dissection

Source – Dolcera, January 2014

High Patent Count, High R&D spend, Low Hype, Low NPEs

#LESDolcera

Transdermal Drug Delivery

Source – Dolcera, January 2014

High Patent Count, High R&D spend, Low Hype, Low NPEs

#LESDolcera

Internet of Things

Source – Dolcera, January 2014

High Patent Count, High R&D spend, High Hype, High NPEs

#LESDolcera

Wearables

Source – Dolcera, January 2014

High Patent Count, High R&D spend, High Hype, High NPEs

#LESDolcera

Smartphones

Source – PCMag, January 2012

High Patent Count, High R&D spend, High Hype, High NPEs

#LESDolcera

Top Plaintiffs & Defendants

Technology Area Plaintiff Defendant

Internet Of Things Brandywine Communications, Penovia, LVL Patent Group, B.E. Technology, Microsoft 25% Samsung, Cisco, Microsoft, Nokia, LG 25%

Wearable Red Pine Point , Pragmatus Mobile, PhatRat Technology, Digimarc, Icon Health

46% Samsung, Apple, Lenovo, Nike, Motorola

38%

Smartphones Motorola, Apple, Nokia, Interdigital, Ericsson 67% Apple, HTC, Samsung, Microsoft,

Motorola 70%

Transdermal Drug delivery Senju Pharmaceutical, Allergan, Kyorin Pharmaceutical,Femina Pharma 98%

Apotex, Lupin, Actavis, Aurobindo Pharma, Hi-Tech Pharmacal Co. 79%

Energy Based Surgical Sealing or Dissection

Boston Scientific, Bovie Medical, ConMed , Cook , Ethicon Endo-Surgery

50% Boston Scientific, Covidien Sales, ConMed, L.C. Medical, Mako Surgical 37%

Medical Stapling Medtronic, Warsaw Orthopedic, Osteotech,Cardica

91%

Nuvasive, Medtronic, Osteotech, Integrated Vascular Interventional Tech., Total

100%

Nano-emulsions in foods Elan Pharma International, Fournier Laboratories Ireland

100%

Teva Pharmaceuticals USA, Ranbaxy Laboratories, Impax Laboratories, Lupin, Biovail Labs

77%

Pollutants and Effects on skin & hair Allergan, Duke University 100%

Watson Pharma, Apotex, Hi-Tech Pharmacal, Sandoz, Total 94%

The smartphone patent wars were in a way unique in HighTech

#LESDolcera Source – Dolcera, January 2014

Thank You!!

^2#C"=C'$7_'

!"#$#%&'(#)*+'?'PCBDAHB@D@BE@AG'

;%"A"C/`A"35Ba823=0%"`=2A'

#LESDolcera

Panelists

24

IP Analytics Internet Services & Products

Maximising IP Value

Computer Technology

Diverse Electronics

#LESDolcera

Appendix

Internet of Things

([+'

(+(',]Q'

,))'

,\+'

+'

-+'

,++'

,-+'

(++'

(-+'

Pb'XPX^.cST?^Z'?T^' d.X'^Sc@' ?YU' ZeUZfTb'XPX^.cST?^Z'^S'P.<'

OfeFX?'.X^OTSPSbg'^S'P.<'

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

R1%/"1/%'-O'7&*129'B'7-Q'E'K99*21//9'

Wearables

R+'-\'

-+'

[Q'[('

+'

,+'

(+'

[+'

Q+'

-+'

R+'

\+'

U5=%272h'^2%;' T5B0'?#=' ?YU'^2%;' Z05B2'X;72#'^2%;' i$"3=2AA'?#='

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

S/#"#N)/'7/.&1-)-2T'B'7-Q'E'K99*21//9'

Pollutants and Effects on Skin & Hair

(+'

)'

Q' Q'['

+'

-'

,+'

,-'

(+'

(-'

P2%0"3' e7/3"#8' e330%6"#' Y050%782%1'eb' YeZj'ZX'

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

!-))8%#1%9'#13'UV/.%9'-1'W+*1'X'Y#*"'B'7-Q'E'K99*21//9'

Energy Based Surgical Sealing or Dissection

\Q)'

Q(]' Q()'Q+('

[+)'

+'

,++'

(++'

[++'

Q++'

-++'

R++'

\++'

)++'

^295850#' Y27C2#'Z=50#Dk='^2%;2%"D2#' !2/#72#'W'!2/#72#' S3&A;$7'^2%;2%"D2#' U08C%2#5='?#='

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

U1/"2T'0#9/3'W8"2*.#)'W/#)*12'-"',*99/.5-1'B'7-Q'E'K99*21//9'

Microfluidics & Microprocessing

,[)'

Q-' QQ'[)'

[['

+'

(+'

Q+'

R+'

)+'

,++'

,(+'

,Q+'

,R+'

j$K5'j53A'O2385#67' SL12%8'^"C"3&7C7'b%2$;' ^2%#5#6' O5C"=/5' ^"3512%#5"'f#590%75C&'

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

(R."-Z8*3*.9'X'(R."-Q"-./99*12'B'7-Q'E'K99*21//9'

Nanoemulsions in Foods

(,'

,('

,+']'

)'

+'

-'

,+'

,-'

(+'

(-'

YeZj' f#53090%' j$K$'j53A'^2%;' @/538'^2'PC8' T07C0='Ze'

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

M#1-/$8)9*-19'*1'>--39'B'7-Q'E'K99*21//9'

Surgical Stapling

QRQ'

Q,Q'

[]' [-' [Q'

+'

-+'

,++'

,-+'

(++'

(-+'

[++'

[-+'

Q++'

Q-+'

-++'

!2/#72#'W'!2/#72#' ^295850#' ^"%85="' ?#C$D90'Z$%65="3' U08C%2#5='

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

W8"2*.#)'W%#Q)*12'B'7-Q'E'K99*21//9'

Transdermal Drug Delivery

]R'

)R'

Q\'

[(' [+'

+'

(+'

Q+'

R+'

)+'

,++'

,(+'

!2/#72#'W'!2/#72#' O57"A5C7$'@/"%A"'^2' .%"#7=$C"#02$7'.0=/#2326507'?#='

P2/A"#'./0%";50'Z&7C0A'eb'

Pb'O2$70/238'W'O0"3C/="%0'

M8$

N/"'-O'Q#%/1

%9'

K99*21//'

7"#193/"$#)',"82',/)*</"T'B'7-Q'E'K99*21//9'